GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

HDM1002 100 mg

Company
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
3 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

3 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for HDM1002 100 mg and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07082114

    A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

    Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 800 participants Est. completion 2027-05-17 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Recruiting NCT NCT07193459

    Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

    Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 360 participants Est. completion 2027-02-01 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Recruiting NCT NCT07594847

    A Study of HDM1002 Tablets on Cardiac Repolarization in Healthy Subjects

    Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 72 participants Est. completion 2026-11-06 1 site Stand-alone
    Other conditions: Healthy Adult Subject
    View official trial listing →
  • Completed NCT NCT06481085

    To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

    Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 324 participants Est. completion 2025-06-30 31 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT06500299

    Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults

    Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 180 participants Est. completion 2024-11-30 Stand-alone
    Other conditions: Overweight and Obesity
    View official trial listing →
  • Status unknown NCT NCT06520540

    HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects

    Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 72 participants Est. completion 2024-12-30 1 site
    Other conditions: Glucagon-Like Peptide-1 Receptor Agonists
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.